JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oyama, N.
Right arrow Articles by Okada, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oyama, N.
Right arrow Articles by Okada, K.

11C-Acetate PET Imaging of Prostate Cancer

Nobuyuki Oyama, MD, PhD1, Hironobu Akino, MD, PhD1, Hiroshi Kanamaru, MD, PhD1, Yuji Suzuki, MD, PhD1, Satoshi Muramoto, MD2, Yoshiharu Yonekura, MD, PhD3, Norihiro Sadato, MD, PhD4, Kazutaka Yamamoto, MD, PhD5 and Kenichiro Okada, MD, PhD1

1 Department of Urology, Fukui Medical University, Fukui, Japan
2 Department of Radiology, Fukui Medical University, Fukui, Japan
3 Biomedical Imaging Research Center, Fukui Medical University, Fukui, Japan
4 National Institute for Physiological Sciences, Okazaki, Japan
5 Wakasa Energy Research Center, Fukui, Japan



View larger version (35K):

[in a new window]
  		FIGURE 1. PET images of prostate obtained using 18F-FDG and 11C-acetate compared with CT image from 71-y-old man with well-differentiated (Gleason sum 2) adenocarcinoma of prostate. (A) CT shows only minimal enlargement of prostate. (B) 18F-FDG PET shows low uptake in prostate, with SUV of 1.97. (C) 11C-Acetate PET shows high uptake in primary prostate cancer lesion, with SUV of 6.41. pr = prostate

 


View larger version (74K):

[in a new window]
  		FIGURE 2. PET images of prostate, lymph node, and bone metastases obtained using 18F-FDG and 11C-acetate from 73-y-old man with poorly differentiated (Gleason sum 7) adenocarcinoma of prostate. (A) 18F-FDG PET shows low uptake in prostate, with SUV of 2.87. (B and C) 18F-FDG uptake was shown in left iliac lymph node metastatic lesion (B) and right pubic bone metastatic lesion (C). (D–F) 11C-Acetate PET shows high uptake in prostate (D), with SUV of 5.45; in left iliac lymph node metastatic lesion (E); and in right pubic bone metastatic lesion (F). bn = bone; ly = lymph node; pr = prostate.

 


View larger version (23K):

[in a new window]
  		FIGURE 3. (A) No correlation was found between Gleason sum and 18F-FDG uptake (P = 0.42). Patients with advanced-stage disease showed higher 18F-FDG uptake than did those with earlier stages (P = 0.03). Weak correlation was found between 18F-FDG and serum PSA value (r = 0.71). (B) No correlation was found among clinical parameters and 11C-acetate uptake. Gl = Gleason sum.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.